{
    "posts": [
      {
        "thread": {
          "uuid": "110b23cb3bdf6d0f0fcb3a4bec10c012931bf820",
          "url": "https://www.americanbankingnews.com/2020/03/22/marshall-wace-llp-lowers-position-in-emergent-biosolutions-inc-nyseebs.html",
          "site_full": "www.americanbankingnews.com",
          "site": "americanbankingnews.com",
          "site_section": "http://feeds.feedburner.com/AmericanBankingNews",
          "site_categories": [
            "financial_news",
            "finance"
          ],
          "section_title": "American Banking News",
          "title": "Marshall Wace LLP Lowers Position in Emergent Biosolutions Inc (NYSE:EBS)",
          "title_full": "Marshall Wace LLP Lowers Position in Emergent Biosolutions Inc (NYSE:EBS)",
          "published": "2020-03-22T16:16:00.000+02:00",
          "replies_count": 0,
          "participants_count": 1,
          "site_type": "news",
          "country": "US",
          "spam_score": 0.0,
          "main_image": "https://www.marketbeat.com/logos/emergent-biosolutions-inc-logo.jpg",
          "performance_score": 0,
          "domain_rank": null,
          "social": {
            "facebook": {
              "likes": 0,
              "comments": 0,
              "shares": 0
            },
            "gplus": {
              "shares": 0
            },
            "pinterest": {
              "shares": 0
            },
            "linkedin": {
              "shares": 0
            },
            "stumbledupon": {
              "shares": 0
            },
            "vk": {
              "shares": 0
            }
          }
        },
        "uuid": "110b23cb3bdf6d0f0fcb3a4bec10c012931bf820",
        "url": "https://www.americanbankingnews.com/2020/03/22/marshall-wace-llp-lowers-position-in-emergent-biosolutions-inc-nyseebs.html",
        "ord_in_thread": 0,
        "parent_url": null,
        "author": "ABMN Staff",
        "published": "2020-03-22T16:16:00.000+02:00",
        "title": "Marshall Wace LLP Lowers Position in Emergent Biosolutions Inc (NYSE:EBS)",
        "text": "Marshall Wace LLP trimmed its stake in Emergent Biosolutions Inc (NYSE:EBS) by 44.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 163,975 shares of the biopharmaceutical company’s stock after selling 130,267 shares during the quarter. Marshall Wace LLP owned about 0.32% of Emergent Biosolutions worth $8,846,000 as of its most recent filing with the SEC.\nOther institutional investors also recently added to or reduced their stakes in the company. Municipal Employees Retirement System of Michigan grew its stake in Emergent Biosolutions by 2.0% during the fourth quarter. Municipal Employees Retirement System of Michigan now owns 13,420 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 260 shares during the period. Comerica Bank grew its stake in Emergent Biosolutions by 0.7% during the fourth quarter. Comerica Bank now owns 42,045 shares of the biopharmaceutical company’s stock worth $2,320,000 after buying an additional 288 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Emergent Biosolutions by 11.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,888 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 294 shares during the period. SG Americas Securities LLC grew its stake in Emergent Biosolutions by 17.5% during the third quarter. SG Americas Securities LLC now owns 3,612 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 538 shares during the period. Finally, Aigen Investment Management LP purchased a new stake in Emergent Biosolutions during the fourth quarter worth approximately $32,000. Hedge funds and other institutional investors own 86.69% of the company’s stock. Get Emergent Biosolutions alerts:\nSeveral research firms have issued reports on EBS. Cowen began coverage on shares of Emergent Biosolutions in a research note on Thursday, March 12th. They set a “hold” rating and a $67.00 price objective for the company. Wells Fargo & Co boosted their price objective on shares of Emergent Biosolutions from $66.00 to $75.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $70.83.\nShares of EBS stock opened at $49.34 on Friday. The company has a market capitalization of $2.76 billion, a PE ratio of 47.90 and a beta of 1.32. The firm has a fifty day simple moving average of $60.13 and a 200-day simple moving average of $55.65. The company has a current ratio of 3.17, a quick ratio of 2.14 and a debt-to-equity ratio of 0.73. Emergent Biosolutions Inc has a twelve month low of $39.11 and a twelve month high of $71.19.\nEmergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.67 by ($0.10). The firm had revenue of $360.40 million during the quarter, compared to analysts’ expectations of $357.18 million. Emergent Biosolutions had a net margin of 4.94% and a return on equity of 14.19%. Emergent Biosolutions’s revenue for the quarter was up 33.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.75 earnings per share. Equities research analysts predict that Emergent Biosolutions Inc will post 3.43 EPS for the current year.\nIn related news, Director Zsolt Harsanyi sold 3,435 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $55.00, for a total value of $188,925.00. Following the sale, the director now directly owns 36,273 shares of the company’s stock, valued at $1,995,015. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, Director Kathryn C. Zoon sold 991 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $60.65, for a total transaction of $60,104.15. Following the completion of the sale, the director now directly owns 16,421 shares in the company, valued at $995,933.65. The disclosure for this sale can be found here . Insiders sold 111,232 shares of company stock valued at $6,844,641 over the last 90 days. Insiders own 14.10% of the company’s stock.\nEmergent Biosolutions Company Profile\nEmergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.\nRead More: Why are gap-down stocks important?\nWant to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS). Receive News & Ratings for Emergent Biosolutions analysts' ratings for Emergent Biosolutions and related companies daily email newsletter . «",
        "highlightText": "",
        "highlightTitle": "",
        "language": "english",
        "external_links": [
          "https://sec.gov/Archives/edgar/data/1193522/000136764420000025/xslF345X03/wf-form4_158353064805074.xml",
          "https://www.sec.gov/Archives/edgar/data/1367644/000136764420000004/xslF345X03/wf-form4_157929595097570.xml",
          "https://sec.gov/Archives/edgar/data/1367644/000136764420000004/xslF345X03/wf-form4_157929595097570.xml",
          "https://marketbeat.com/market-data/gap-down-stocks/",
          "https://www.marketbeat.com/stocks/NYSE/EBS/sec-filings",
          "https://marketbeat.com/newsletter/default.aspx",
          "https://www.marketbeat.com/stocks/NYSE/EBS/sec-filings/",
          "https://www.holdingschannel.com/hedge-funds/holding-ebs",
          "https://www.marketbeat.com/market-data/gap-down-stocks/",
          "https://www.marketbeat.com/market-data/gap-down-stocks",
          "https://marketbeat.com/stocks/NYSE/EBS/sec-filings/",
          "https://www.holdingschannel.com/hedge-funds/holding-ebs/",
          "https://holdingschannel.com/hedge-funds/holding-ebs/",
          "https://www.marketbeat.com/newsletter/default.aspx",
          "https://www.sec.gov/Archives/edgar/data/1193522/000136764420000025/xslF345X03/wf-form4_158353064805074.xml"
        ],
        "external_images": null,
        "entities": {
          "persons": [
            {
              "name": "zurcher kantonalbank zurich cantonalb",
              "sentiment": "none"
            }
          ],
          "organizations": [
            {
              "name": "marshall wace llp lowers position in emergent biosolutions inc",
              "sentiment": "none"
            },
            {
              "name": "marshall wace llp",
              "sentiment": "none"
            },
            {
              "name": "emergent biosolutions inc",
              "sentiment": "none"
            },
            {
              "name": "sec",
              "sentiment": "none"
            },
            {
              "name": "comerica bank",
              "sentiment": "none"
            }
          ],
          "locations": [
            {
              "name": "michigan",
              "sentiment": "none"
            }
          ]
        },
        "rating": null,
        "crawled": "2020-03-22T17:07:36.013+02:00"
      }
    ]
}